Suchergebnisse

Grant sponsor: Instituto de Salud Carlos III-FEDER; Grant number: PI11/01889; Grant sponsor: "Accion Transversal del Cancer, "approved on the Spanish Ministry Council on the 11th October 2007; Grant sponsor: Instituto de Salud Carlos III-FEDER; Grant numbers: PI08/1770, PI08/0533, PI08/1359, PI09/00773-Cantabria, PI09/01286-Le on, PI09/01903-Valencia, PI09/02078-Huelva, PI09/01662-Granada, PI11/01889-FEDER, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI14/0613, PI15/00069, PI15/00914, PI15/01032; Grant sponsor: Regional Government of the Basque Country; Grant sponsor: Consejería de Sanidad de la Región de Murcia; Grant sponsor: European Commission grants FOOD-CT-2006–036224-HIWATE; Grant sponsor: Spanish Association Against Cancer (AECC) Scientific Foundation; Grant sponsor: Catalan Government DURSI grant; Grant number: 2014SGR647; Grant sponsor: Fundación Caja de Ahorros de Asturias and by the University of Oviedo ; Kogevinas, M., Espinosa, A., Castelló, A., Gómez-Acebo, I., Guevara, M., Martin, V., Amiano, P., Alguacil, J., Peiro, R., Moreno, V., Costas, L., Fernández-Tardón, G., Jimenez, J.J., Marcos-Gragera, R., Perez-Gomez, B., Llorca, J., Moreno-Iribas, C., Fernández-Villa, T., Oribe, M., Aragones, N., Papantoniou, K., Pollán, M., Castano-Vinyals, G., Romaguera, D.

The study was supported by the "Acción Transversal del Cáncer", approved on the Spanish Ministry Council on the 11 October 2007, by the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), by the Instituto de Salud Carlos III grants, co-funded by FEDER funds -a way to build Europe-PI08/1770, PI09/0773, PI12/00715, PI09/1903,PI09/2078; PI09/1662; PI11/01403; PI12/00150;PI12/00488;PI15/00914;PI17CIII_00034;by the Fundación Marqués de Valdecilla grant API 10/09, by the Consejería de Salud of the Junta de Andalucía grant 2009-S0143, by the Conselleria de Sanitat of the Generalitat Valenciana grant AP061/10, by the Regional Government of the Basque Country, by the Fundación Caja de Ahorros de Asturias, by the University of Oviedo and by the Spanish Ministry of Economy and Competitiveness Juan de la Cierva de Incorporación grant IJCI-2014-20900. ; Gutiérrez-González, E., Castelló, A., Fernández-Navarro, P., Castaño-Vinyals, G., Llorca, J., Salas, D., Salcedo-Bellido, I., Aragonés, N., Fernández-Tardón, G., Alguacil, J., Gracia-Lavedan, E., García-Esquinas, E., Gómez-Acebo, I., Amiano, P., Romaguera, D., Kogevinas, M., Pollán, M., Pérez-Gómez, B.

This work was partially funded by the public grants from theCatalan Government (2014SGR756, 2017SGR1085, 2017SGR733,SLT006/17/76), and European Regional Development Fund-ERDF, bythe "Accion Transversal del Cancer", approved on the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773-Cantabria,PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI11/01810, PI14/01219, PI11/02213, PIE16/00049, PI17/01179), by the Fundación Marqués de Valdecilla (API 10/09), by the Red Temática de Investigación del Cáncer (RTICC) del ISCIII(RD12/0036/0036), by the Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, salud 201200057018tra), by the Conselleria de Sanitat ofthe Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP00310), by the Regional Government of the Basque Country, by the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government-Agency for Management of University and Research Grants (AGAUR) grants 2014SGR647 and 2014SGR850. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya ; Peremiquel-Trillas, P., Benavente, Y., Martín-Bustamante, M., Casabonne, D., Pérez-Gómez, B., Gómez-Acebo, I., Oliete-Canela, A., Diéguez-Rodríguez, M., Tusquets, I., Amiano, P., Mengual, L., Ardanaz, E., Capelo, R., Molina de la Torre, A.J., Salas Trejo, D., Fernández-Tardón, G., Lope, V., Jimenez-Moleon, J.J., Marcos-Gragera, R., Dierssen-Sotos, T., Azpiri, M., Muñoz, M., Guevara, M., Fernández-Villa, T., Molina-Barceló, A., Aragonés, N., Pollán, M., Castaño-Vinyals, G., Alguacil, J., Kogevinas, M., de ...

Tis work was supported by the 'Acción Transversal del Cancer', approved by the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded by FEDER funds –'a way to build Europe' (grants PI08/1770, PI08/0533, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, PI09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/00613, and PI15/00069). Support was also provided by the Fundación Marqués de Valdecilla (grant API 10/09); the Junta de Castilla y León (grant LE22A10–2); the Consejería de Salud of the Junta de Andalucía (2009-S0143); the Conselleria de Sanitat of the Generalitat Valenciana (grant AP 061/10); the Recercaixa (grant 2010ACUP 00310); the Regional Government of the Basque Country; the Consejería de Sanidad de la Región de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE; the Fundación Científca Asociación Española Contra el Cáncer (AECC); the Catalan Government DURSI (grant This work was supported by the 'Accion Transversal del Cancer', approved by the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded by FEDER funds -'a way to build Europe' (grants PI08/1770, PI08/0533, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, PI09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/00613, and PI15/00069). Support was also provided by the Fundacion Marques de Valdecilla (grant API 10/09); the Junta de Castilla y Leon (grant LE22A10-2); the Consejeria de Salud of the Junta de Andalucia (2009-S0143); the Conselleria de Sanitat of the Generalitat Valenciana (grant AP 061/10); the Recercaixa (grant 2010ACUP 00310); the Regional Government of the Basque Country; the Consejeria de Sanidad de la Region de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE; the Fundacion Cientifica Asociacion Espanola Contra ...

The study was partially funded by the "Accion Transversal del Cancer", approved on the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER, a way to build Europe (PI08/1770, PI08/0533, PI08/1359, PI09/00773-Cantabria, PI09/01286-León, PI09/01903-Valencia, PI09/02078-Huelva, PI09/ 01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613), by the Fundación Marqués de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), by the Consejería de Educación, Junta de Castilla y León (LE22A10-2), by the Consejería de Salud, Junta de Andalucía (2009-S0143), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejería de Sanidad y Política Social, Comunidad Autónoma de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by the Scientific Foundation, Spanish Association Against Cancer (AECC), by the Agency for Management of University and Research Grants (AGAUR) of the Catalan Government grant 2017SGR723, by the Fundación Bancaria Caja de Ahorros de Asturias and by the University of Oviedo. ; Vallès, X., Alonso, M.H., López-Caleya, J.F., Díez-Obrero, V., Dierssen-Sotos, T., Lope, V., Molina-Barceló, A., Chirlaque, M.D., Jiménez-Moleón, J.J., Fernández Tardón, G., Castilla, J., Amiano, P., Capelo, R., Castaño-Vinyals, G., Guinó, E., Molina de la Torre, A.J., Moreno-Iribas, C., Pérez Gómez, B., Aragonés, N., Llorca, J., Martín, V., Kogevinas, M., Pollán, M., Moreno, V.

The study was partially funded by the "Acción transversal del cancer", approved by the Spanish Ministry council on 11 October 2007, by the Instituto de Salud Carlos III-Feder (pi08/1770, pi08/0533, pi08/1359, pi09/00773-Cantabria, pi09/01286-León, pi09/01903-Valencia, pi09/02078-Huelva, pi09/01662-Granada, pi11/01403, pi11/01889-Feder, pi11/00226, pi11/01810, pi11/02213, pi12/00488, pi12/00265, pi12/01270, pi12/00715, pi12/00150, pi14/01219, pi14/0613), by the Fundación Marqués de Valdecilla (api 10/09), by the ICGC International Cancer Genome Consortium cll (the icgc cll-genome project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (rd12/0036/0036)), by the Junta de Castilla y León (le22a10-2), by the Consejería de Salud of the Junta de Andalucía (2009-s0143), by the Conselleria de Sanitat of the Generalitat Valenciana (ap_061/10), by the Recercaixa (2010acup 00310), by the regional government of the Basque country, by the Consejería de Sanidad de la Región de Murcia, by the European Commission Grants Food-ct-2006-036224-hiwate, by the Spanish Association Against Cancer (AECC) scientific foundation, by the Catalan Government dursi grant 2014sgr647, by the Fundación Caja de Ahorros de Asturias and by the University of Oviedo. ; Olmedo-Requena, R., González-Donquiles, C., Dávila-Batista, V., Romaguera, D., Castelló, A., de la Torre, A.J.M., Amiano, P., Dierssen-Sotos, T., Guevara, M., Fernández-Tardón, G., Lozano-Lorca, M., Alguacil, J., Peiró, R., Huerta, J.M., Gracia-Lavedan, E., Aragonés, N., Fernández-Villa, T., Solans, M., Gómez-Acebo, I., Castaño-Vinyals, G., Kogevinas, M., Pollán, M., Martín, V.

This work was partially funded by the "Accion Transversal del Cancer", approved on the Spanish Ministry Council on the 11th October 2007; The Instituto de Salud Carlos III-FEDER [PI08/1770, PI08/0533, PI08/1359, PI09/00773-Cantabria, PI09/01286-León, PI09/01903-Valencia, PI09/02078-Huelva, PI09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032]; The Fundación Marqués de Valdecilla [API 10/09]; The ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)); The Junta de Castilla y León [LE22A10–2]; The Consejería de Salud of the Junta de Andalucía [2009-S0143]; The Conselleria de Sanitat of the Generalitat Valenciana [AP_061/10]; The Recercaixa [2010ACUP 00310]; The Regional Government of the Basque Country; The Consejería de Sanidad de la Región de Murcia; The European Commission [grants FOODCT-2006-036224-HIWATE]; The Spanish Association Against Cancer (AECC) Scientific Foundation; The Catalan Government DURSI [grant 2014SGR647]; The Fundación Caja de Ahorros de Asturias; and the University of Oviedo. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. ; Gómez-Acebo, I., Dierssen-Sotos, T., De Pedro, M., Pérez-Gómez, B., Castaño-Vinyals, G., Fernández-Villa, T., Palazuelos-Calderón, C., Amiano, P., Etxeberria, J., Benavente, Y., Fernández-Tardón, G., Salcedo-Bellido, I., Capelo, R., Peiró, R., Marcos-Gragera, R., Huerta, J.M., Tardón, A., Barricarte, A., Altzibar, J.-M., Alonso-Molero, J., Dávila-Batista, V., Aragonés, N., Pollán, M., Kogevinas, M., Llorca, J.

The study was partially funded by the "Accion Transversal del Cancer", approved by the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773-Cantabria, PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI17CIII/00034), by the Fundación Marqués de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), by the Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, salud201200057018tra), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government- Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, by the Fundación Caja de Ahorros de Asturias and by the University of Oviedo. and IDIBELL is aare members of the CERCA Programme, Generalitat de Catalunya. RZ-R was supported by the "Miguel Servet" program (CP15/00100) from the Institute of Health Carlos III (Co-funded by the European Social Fund (ESF)—ESF investing in your future). ; Vitelli-Storelli, F., Zamora-Ros, R., Molina, A.J., Fernández-Villa, T., Castelló, A., Barrio, J.P., Amiano, P., Ardanaz, E., Obón-Santacana, M., Gómez-Acebo, I., Fernández-Tardón, G., Molina-Barceló, A., Alguacil, J., ...

Instituto de Salud Carlos III (Red INMA G03/176, CB06/02/0041), (FIS-PI13/2429, PI041436, PI042018, PI06/0867, PI07/0252, PI08/1151, PI09/02311, y FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314, 09/02647, y MS13/00054), Generalitat de Catalunya-CIRIT 1999SGR 00241, Conselleria de Sanitat, Generalitat Valenciana, Departamento de Salud del Gobierno Vasco (2005111093 y 2009111069), Gobierno Provincial de Guipúzcoa (DFG06/004 and DFG08/001), Obra Social Cajastur, Universidad de Oviedo, European Union Commission (QLK4-1999-01422, QLK4-2002-00603 and CONTAMED FP7-ENV-212502), Consejería de Salud de la Junta de Andalucía (183/07), y Fundació Roger Torné.

Fundamentos: Los estudios publicados no son concluyentes sobre el impacto de determinadas exposiciones ocupacionales en el embarazo, evidenciando la necesidad de considerar el doble rol, profesional y familiar, de las mujeres. El objetivo del presente trabajo fue evaluar el efecto de la situación laboral y de la carga doméstica de trabajo en la duración de la gestación y en el desarrollo fetal. Métodos: Mediante modelos de regresión univariante y multivariante, se estudió la asociación entre partos pretérmino (PPT) (<37 semanas), recién nacidos con bajo peso a término (BPT) (<2500g) y pequeños para su edad gestacional (PEG) (

The study was partially funded by the "Acción Transversal del Cáncer", approved by the Spanish Ministry Council on 11 October 2007, by the Instituto de Salud Carlos III-FEDER, Spanish Government (PI08/1770, PI08/0533, PI08/1359, PI09/00773-Cantabria, PI09/01286-León, PI09/01903-Valencia, PI09/02078-Huelva, PI09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613), by the Fundación Marqués de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), by the Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (2009-S0143), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government DURSI grant 2014SGR647, by the Fundación Caja de Ahorros de Asturias, and by the University of Oviedo. Veronica Dávila-Batista: predoctoral contract financed by the Junta de Castilla y Leon and the European Social Fund (EDU/1083/2013), and she also obtained a CIBERESP grant for a stay in an international research centre. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019–2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. ; Davila-Batista, V., Molina, A.J., Fernández-Villa, T., Romaguera, D., Pérez-Gómez, B., Vilorio-Marqués, L., Dierssen-Sotos, T., Altzibar, J.M., Moreno, V., Ardanaz, E., ...

The study was partially funded by the 'Accion Transversal del Cancer', approved on the Spanish Ministry Council on 11 October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773-Cantabria, PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/01662- Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213,PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI17CIII/00034, PI18/00181), by the Fundación Marqués de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (the ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), by the Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, salud 201200057018tra), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejería de Sanidad de la Región de Murcia, by the European Commission (grants FOOD-CT-2006-036224-HIWATE), by the Spanish Association Against Cancer (AECC) Scientific Foundation (GCTRA18022MORE), by the Catalan Government-Agency for Management of University and Research Grants (AGAUR) (grants 2017SGR723 and 2014SGR850), by the Fundación Caja de Ahorros de Asturias, and by the University of Oviedo. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. ; Alonso-Molero, J., Molina, A.J., Jiménez-Moleón, J.J., Pérez-Gómez, B., Martin, V., Moreno, V., Amiano, P., Ardanaz, E., De Sanjose, S., Salcedo, I., Fernandez-Tardon, G., Alguacil, J., Salas, D., Marcos-Gragera, R., Chirlaque, M.D., Aragonés, N., Castaño-Vinyals, G., Pollán, M., Kogevinas, M., Llorca, J.

Tis work was supported by the 'Acción Transversal del Cancer', approved by the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded by FEDER funds –'a way to build Europe' [grants PI08/1770, PI08/0533, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, PI09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/00613, PI17/00092 and PI15/00069]. Support was also provided by the Fundación Marqués de Valdecilla (grant API 10/09]; the Junta de Castilla y León [grant LE22A10-2]; the Consejería de Salud of the Junta de Andalucía [2009-S0143]; the Conselleria de Sanitat of the Generalitat Valenciana [grant AP 061/10]; the Recercaixa [grant 2010ACUP 00310]; the Regional Government of the Basque Country; the Consejería de Sanidad de la Región de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE; the Spanish Association Against Cancer (AECC) Scientifc Foundation; the Catalan Government DURSI [grants 2017SGR723 and 2014SGR850]; the Fundación Caja de Ahorros de Asturias; the University of Oviedo; Societat Catalana de Digestologia; and COST action CA17118 Transcoloncan. ISGlobal and IDIBELL are members of the CERCA Programme, Generalitat de Catalunya.

Zinc is a key trace element in normal prostate cell metabolism, and is decreased in neoplastic cells. However, the association between dietary zinc and prostate cancer (PC) in epidemiologic studies is a conflicting one. Our aim was to explore this association in an MCC-Spain case-control study, considering tumor aggressiveness and extension, as well as genetic susceptibility to PC. 733 incident cases and 1228 population-based controls were included for this study. Dietary zinc was assessed using a food frequency questionnaire, and genetic susceptibility was assessed with a single nucleotide polymorphisms (SNP)-based polygenic risk score (PRS). The association between zinc intake and PC was evaluated with mixed logistic and multinomial regression models. They showed an increased risk of PC in those with higher intake of zinc (Odds Ratio (OR) tertile 3vs1: 1.39; 95% Confidence interval (CI):1.00⁻1.95). This association was mainly observed in low grade PC (Gleason = 6 RRR tertile 3vs1: 1.76; 95% CI:1.18⁻2.63) as well as in localized tumors (cT1-cT2a RRR tertile 3vs1: 1.40; 95% CI:1.00⁻1.95) and among those with higher PRS (OR tertile 3vs1: 1.50; 95% CI:0.89⁻2.53). In conclusion, a higher dietary zinc intake could increase the risk of low grade and localized tumors. Men with higher genetic susceptibility0020might also have a higher risk of PC associated with this nutrient intake. ; The study was supported by the "Acción Transversal del Cáncer", approved on the Spanish Ministry Council on the 11 October 2007, by the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), by the Instituto de Salud Carlos III grants, co-funded by FEDER funds -a way to build Europe- PI08/1770, PI09/0773, PI12/00715, PI09/1903,PI09/2078; PI09/1662; PI11/01403; PI12/00150; PI12/00488; PI15/00914; PI17CIII_00034;by the Fundación Marqués de Valdecilla grant API 10/09, by the Consejería de Salud of the Junta de Andalucía grant 2009-S0143, by the Conselleria de Sanitat of the Generalitat Valenciana grant AP061/10, by the Regional Government of the Basque Country, by the Fundación Caja de Ahorros de Asturias, by the University of Oviedo and by the Spanish Ministry of Economy and Competitiveness Juan de la Cierva de Incorporación grant IJCI-2014-20900. ; Sí

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background: Evidence for a protective role of physical activity against development of stomach cancer is yet inconclusive. We studied the association of domain-specific physical activity and the risk of gastric adenocarcinoma (GAC), by site and histology, in the MCC-Spain case-control study. Methods: 428 histologically confirmed GAC cases (67% men) including the gastro-esophageal region and 3225 controls were included. Cases were recruited in hospitals from 10 different Spanish regions, whereas population controls were randomly selected within the respective hospitals' catchment areas. A physical activity (PA) questionnaire was used to gather information on household and recreational activities, allowing estimation of PA volume (in metabolic equivalents (MET)-min/week). Participants also reported the intensity of working PA and daily sitting time. Questionnaire data on diet, lifestyles and clinical variables including Helicobacter pylori serology were available. Adjusted odds ratios (OR) of GAC were estimated for domains of physical activity, stratifying by sex, site (cardia vs. non-cardia), and Lauren classification (intestinal vs. diffuse). Results: Household physical activity (HPA) showed a strong inverse association with GAC, observed for both cardia and non-cardia tumours. Risk of overall gastric cancer was 50% lower risk among participants in the highest HPA category (OR = 0.50, 95%CI: 0.38, 0.66). Recreational physical activity (RPA) was also associated with lower overall GAC risk (OR = 0.68, 95% CI: 0.52, 0.88), particularly at moderate levels of intensity such as walking (OR = 0.61, 95% CI: 0.46, 0.79). The protective effect of RPA was strongest for non-cardia tumours. Sedentary time was not related to GAC risk (p-trend = 0.392), but the potential protective effect of RPA was restricted to non-sedentary participants. Conclusions: Both household and recreational physical activities were independently related to lower GAC risk in the MCC-Spain study. ; The study was partially funded by the "Accion Transversal del Cancer", approved by the Spanish Ministry Council on 11 October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, PI09/01662, PI11/01403, PI11/01889, PI12/00265), the Fundación Marqués de Valdecilla (API 10/09), the Junta de Castilla y León (LE22A10±2), the Consejería de Salud of the Junta de Andalucía (2009-S0143), the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), the Recercaixa (2010ACUP 00310), the Regional Government of the Basque Country, the Consejería de Sanidad de la Región de Murcia, the European Commission grants FOOD-CT-2006±036224-HIWATE, the Spanish Association Against Cancer (AECC) Scientific Foundation, the Catalan Government DURSI grant 2014SGR647, the Fundación Caja de Ahorros de Asturias and by the University of Oviedo